Y H van Beurden1, S Nezami2, C J J Mulder2, C M J E Vandenbroucke-Grauls3. 1. Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands; Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: y.vanbeurden@vumc.nl. 2. Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands. 3. Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
OBJECTIVE: A frequent complication of Clostridium difficile infection (CDI) is recurrent disease. The aim of this study was to determine whether early recurrence risk was higher after infection with ribotype 027 (outbreak strain) compared with infection with endemic strain types of C. difficile. METHODS: Consecutive patients diagnosed with CDI between May 2013 and March 2014 were included (outbreak strain, and non-outbreak strains). Patients who developed recurrent CDI within 30 days after completion of CDI treatment, were compared with patients without a recurrence. Medical charts were reviewed for demographic and clinical characteristics. General practitioners were contacted to complete data about the occurrence of recurrent CDI, and the use of medication after hospital discharge. RESULTS: In total, 135 patients were at risk for the development of recurrent CDI; 74 patients were infected by ribotype 027, and 61 patients by other ribotypes. Thirty-nine patients (29%) developed recurrent CDI within 30 days after completion of CDI treatment. In multivariable analysis, age ≥70 years (HR 3.05, 95% CI 1.54-6.03), and a duration of CDI treatment ≥11 days (HR 1.92, 95% CI 1.00-3.69) were clearly associated with recurrence; infection with ribotype 027 showed a HR of 1.72 (95% CI 0.88-3.33). CONCLUSION: During this outbreak of C. difficile in a tertiary care centre, age and a prolonged duration of CDI therapy (which is most likely a marker of underlying disease severity) were the main risk factors for recurrent CDI. This points to host factors as more important predictors for recurrent CDI than strain type or antibiotic use.
OBJECTIVE: A frequent complication of Clostridium difficileinfection (CDI) is recurrent disease. The aim of this study was to determine whether early recurrence risk was higher after infection with ribotype 027 (outbreak strain) compared with infection with endemic strain types of C. difficile. METHODS: Consecutive patients diagnosed with CDI between May 2013 and March 2014 were included (outbreak strain, and non-outbreak strains). Patients who developed recurrent CDI within 30 days after completion of CDI treatment, were compared with patients without a recurrence. Medical charts were reviewed for demographic and clinical characteristics. General practitioners were contacted to complete data about the occurrence of recurrent CDI, and the use of medication after hospital discharge. RESULTS: In total, 135 patients were at risk for the development of recurrent CDI; 74 patients were infected by ribotype 027, and 61 patients by other ribotypes. Thirty-nine patients (29%) developed recurrent CDI within 30 days after completion of CDI treatment. In multivariable analysis, age ≥70 years (HR 3.05, 95% CI 1.54-6.03), and a duration of CDI treatment ≥11 days (HR 1.92, 95% CI 1.00-3.69) were clearly associated with recurrence; infection with ribotype 027 showed a HR of 1.72 (95% CI 0.88-3.33). CONCLUSION: During this outbreak of C. difficile in a tertiary care centre, age and a prolonged duration of CDI therapy (which is most likely a marker of underlying disease severity) were the main risk factors for recurrent CDI. This points to host factors as more important predictors for recurrent CDI than strain type or antibiotic use.
Authors: Tessel M van Rossen; Laura J van Dijk; Martijn W Heymans; Olaf M Dekkers; Christina M J E Vandenbroucke-Grauls; Yvette H van Beurden Journal: Therap Adv Gastroenterol Date: 2021-01-09 Impact factor: 4.409
Authors: Giles Major; Lucy Bradshaw; Nafisa Boota; Kirsty Sprange; Mathew Diggle; Alan Montgomery; Aida Jawhari; Robin C Spiller Journal: Gut Date: 2018-09-25 Impact factor: 23.059
Authors: Judong Shen; Devan V Mehrotra; Mary Beth Dorr; Zhen Zeng; Junhua Li; Xun Xu; David Nickle; Emily R Holzinger; Aparna Chhibber; Mark H Wilcox; Rebecca L Blanchard; Peter M Shaw Journal: mSphere Date: 2020-05-06 Impact factor: 4.389
Authors: Sarah L Erickson; Laurie Alston; Kristoff Nieves; Thomas K H Chang; Sridhar Mani; Kyle L Flannigan; Simon A Hirota Journal: FASEB J Date: 2019-12-17 Impact factor: 5.191